Johns Hopkins researchers develop intranasal DNA vaccine targeting drug-resistant tuberculosis

Researchers developed an intranasal DNA fusion vaccine targeting drug-tolerant tuberculosis persisters. In preclinical models, it improved bacterial clearance and reduced lung inflammation.